- Home
- CAC vs EVMN Comparison
CAC vs EVMN Comparison
Compare CAC & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAC | EVMN |
|---|---|---|
| Founded | 1875 | 2020 |
| Country | United States | United States |
| Employees | N/A | 48 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 857.1M | 825.5M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | CAC | EVMN |
|---|---|---|
| Price | $49.52 | $22.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $47.00 | $43.88 |
| AVG Volume (30 Days) | 77.7K | ★ 341.8K |
| Earning Date | 04-28-2026 | 06-11-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 6.08 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $41,739,000.00 | N/A |
| Revenue This Year | $19.15 | N/A |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | $38.29 | ★ N/A |
| Revenue Growth | ★ 16.96 | N/A |
| 52 Week Low | $35.00 | $13.89 |
| 52 Week High | $53.71 | $33.20 |
Technical Indicators
Market Signals| Indicator | CAC | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 54.55 | 45.97 |
| Support Level | $47.12 | $21.39 |
| Resistance Level | $51.57 | $23.08 |
| Average True Range (ATR) | 1.10 | 1.43 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 78.19 | 45.87 |
Price Performance
Historical ComparisonAbout CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.